Elie Traer
Overview
Explore the profile of Elie Traer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2694
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Sa H, DeLoughery T, Kaempf A, Lachowiez C, Leonard J, Mathews R, et al.
Leuk Lymphoma
. 2024 Sep;
66(1):34-43.
PMID: 39291957
Thrombosis rates among young adults receiving asparaginase (ASP) for acute lymphoblastic leukemia (ALL) can reach 34%, with highest risk during induction. Our institution implemented a standard practice of 1 mg/kg/day...
2.
Issa G, Aldoss I, Thirman M, DiPersio J, Arellano M, Blachly J, et al.
J Clin Oncol
. 2024 Aug;
43(1):75-84.
PMID: 39121437
Purpose: Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with -rearranged...
3.
Hoff F, Blum W, Huang Y, Welkie R, Swords R, Traer E, et al.
Blood Adv
. 2024 Aug;
8(20):5297-5305.
PMID: 39110987
Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ...
4.
Pino J, Posso C, Joshi S, Nestor M, Moon J, Hansen J, et al.
Cell Rep Med
. 2024 Jan;
5(1):101359.
PMID: 38232702
Acute myeloid leukemia is a poor-prognosis cancer commonly stratified by genetic aberrations, but these mutations are often heterogeneous and fail to consistently predict therapeutic response. Here, we combine transcriptomic, proteomic,...
5.
Brunner A, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, et al.
Am J Hematol
. 2023 Nov;
99(2):E32-E36.
PMID: 37994196
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised...
6.
Joshi S, Pittsenbarger J, Kennedy V, Peretz C, Perl A, Smith C, et al.
Am J Hematol
. 2023 Oct;
98(12):E364-E368.
PMID: 37815132
No abstract available.
7.
Joshi S, Piehowski P, Liu T, Gosline S, McDermott J, Druker B, et al.
Annu Rev Pharmacol Toxicol
. 2023 Sep;
64:455-479.
PMID: 37738504
Proteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often...
8.
Mohebnasab M, Li P, Hong B, Dunlap J, Traer E, Fan G, et al.
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37685882
Cytogenetically cryptic acute promyelocytic leukemia (APL) is rare, characterized by typical clinical and morphological features, but lacks t(15;17)(q24;q21)/ translocation seen in conventional karyotyping or FISH. The prompt diagnosis and treatment...
9.
Oyogoa E, Traer E, Tyner J, Lachowiez C
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509251
Frontline acute myeloid leukemia (AML) treatment is determined by a combination of patient and genetic factors. This includes patient fitness (i.e., comorbidities that increase the risk of treatment-related mortality) and...
10.
Khanna V, Azenkot T, Liu S, Gilbert J, Cheung E, Lau K, et al.
Leuk Res
. 2023 Jun;
131:107331.
PMID: 37263072
No abstract available.